Incidence of Transcranial Doppler–Detected Cerebral Microemboli in Patients Referred for Echocardiography

David C. Tong, MD; Ann Bolger, MD; Gregory W. Albers, MD

Background and Purpose Transcranial Doppler can detect cerebral microemboli. These emboli may be a risk factor for embolic stroke. We studied the prevalence of microemboli in patients referred for echocardiography.

Methods Forty-two patients were evaluated. Patients were studied with continuous monitoring over one middle cerebral artery for 30 minutes, and the number of microemboli was recorded. Patients were divided into three groups, those with prosthetic heart valves (group A, n=15), atrial fibrillation (group B, n=14), and no major cardiac risk factor (group C, n=14).

Results Seventeen percent (7 of 42) of all patients had microemboli. In group A, 5 of 15 (33%) had microemboli. In group B, 2 of 13 (15%) patients had microemboli. Twenty-five percent (7 of 28) of patients in groups A and B combined (A+B) had microemboli. No patients (0 of 14) in group C had microemboli. Groups A and A+B had significantly more emboli than group C (P<.05). Prosthetic heart valve patients with emboli more commonly had a history of prior stroke than valve patients without emboli (3 of 5 versus 2 of 10). The number of emboli seen per 30-minute monitoring session was greater in patients with a prior history of stroke than in patients without (10 microemboli versus 3).

Conclusions Microemboli can be found in a significant percentage of selected patients referred for echocardiography. The prevalence of microembolism is greater in patients with a known high risk of embolization (eg, prosthetic valves) and less in patients with a lower risk of embolization (eg, atrial fibrillation). These microemboli may be associated with an increased prevalence of previous stroke in patients with prosthetic valves. (Stroke. 1994;25:2138-2141.)

Key Words • Doppler • echocardiography • embolism
Tong et al  TCD-Detected Cerebral Microemboli 2139

TABLE 2. Patient Group Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (n=42)</th>
<th>Emboli-Positive (n=7)</th>
<th>Emboli-Negative (n=35)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>42 (100)</td>
<td>7 (100)</td>
<td>35 (100)</td>
<td>NS</td>
</tr>
<tr>
<td>Diabetes</td>
<td>10 (24)</td>
<td>5 (71)</td>
<td>5 (14)</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>Hypertension</td>
<td>28 (67)</td>
<td>5 (71)</td>
<td>23 (66)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>12 (26)</td>
<td>2 (29)</td>
<td>8 (23)</td>
<td>NS</td>
</tr>
<tr>
<td>Smoking</td>
<td>29 (69)</td>
<td>3 (43)</td>
<td>26 (74)</td>
<td>NS</td>
</tr>
<tr>
<td>Ethanol consumption</td>
<td>20 (48)</td>
<td>2 (28)</td>
<td>18 (51)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values in parentheses are percent.
*Emboli-positive versus emboli-negative groups.

Variables among groups. The level of significance for the statistical analyses was P<.05.

Results

Forty-two patients were enrolled in the study (Table 1). All were men. The average age was 65.2 years. There was no significant age difference among groups. There were no statistically significant differences among groups except for a higher prevalence of diabetes in the emboli-positive subgroup (P<.05). The specific types of patients included in each subgroup are summarized in Table 2.

Microemboli (Figure) were detected in 7 of 42 patients studied (Table 3). Five of 15 (33%) valve replacement patients had emboli. Microemboli were detected in 2 of 5 patients with mechanical valves (1 aortic, 1 mitral) and 3 of 10 patients with porcine valves (all aortic). Two of 13 (15%) AF patients had emboli. None of the patients in group C (0 of 14) had emboli, including 3 patients with chronic left ventricular thrombi. The number of patients with emboli detected was significantly greater in group A than group C (P<.05). If the two high-risk subgroups were combined, the prevalence of emboli was 25% (7 of 28).
This was also significantly greater than in group C (P<.05).

The majority of patients (30 of 42) were taking warfarin (14) or aspirin (16) at the time of the study. In group A, 12 of 15 (6 warfarin, 6 aspirin) were being treated; 11 of 13 (6 warfarin, 5 aspirin) in group B and 7 of 14 (2 warfarin, 5 aspirin) in group C were being treated. Overall, only 1 patient was subtherapeutic on warfarin. This patient had AF and an international normalized ratio (INR) of 1.4. Of the emboli-positive patients, 5 of 7 were taking warfarin. All were therapeutically anticoagulated (INR, 2.0 to 3.0). None were taking aspirin. Both porcine valve patients with emboli were not receiving antithrombotic treatment. Overall, however, there was no definite relationship between treatment and the presence of emboli.

The prevalence of stroke or TIA was 18 of 42 events (43%) (Table 3). Of these events, 5 were recent (<1 week since start of symptoms), and 13 were 1 week or more old. The prevalence of stroke or TIA was similar between the emboli-positive (3 of 7 or 43%; 2 old, 1 recent) and emboli-negative subgroups (15 of 35 or 43%; 10 old, 5 recent). However, the stroke prevalence in prosthetic valve patients was greater in patients with emboli. Sixty percent (3 of 5) of these patients had prior stroke (2 old, 1 recent) versus 20% (2 of 10; 1 old, 1 recent) of valve patients without emboli. This did not reach statistical significance.

There was no apparent relationship between the acuity of stroke and the presence of microemboli. No patients with acute symptoms (0 of 5) had microemboli compared with 3 of 13 patients with a history of prior stroke. However, of 5 patients with acute stroke, there were 4 in group C, 0 in group B, and 1 in group A.

Fourteen patients had carotid ultrasound examinations. Of the emboli-positive group, 3 of 7 had a carotid ultrasound performed, and none had a significant stenosis. Two other patients had emboli detected in other vascular distributions (as part of another study). Of the last 2 emboli-positive patients, 1 was relatively young (46 years old) and had a bioprosthetic aortic valve replacement. The other had a history of AF and severe congestive heart failure.

The number of microemboli varied from 1 to 17 per 30 minutes (Table 4). The lowest rate was in a patient with AF (1 per 30 minutes). The highest rate was seen in a patient with a mechanical valve replacement (17 per 30 minutes). The average number of emboli per monitoring session was 1.8 per 30 minutes (range, 2 to 8) in the porcine valve replacement group and 8 per 30 minutes (range, 2 to 17) in the mechanical valve group. The embolization rate was higher in the patients with prior stroke compared with those without prior stroke. In the 3 patients with emboli and stroke, the average number of emboli was 10 per 30 minutes. In the patients with emboli and no prior stroke, the rate was 3 per 30 minutes (Table 4). This did not reach statistical significance.

**Discussion**

We found that TCD-detected microemboli are not uncommon in groups at high risk for embolic stroke. Although our population had a predominance of aortic and/or porcine valves, and the majority were taking therapeutic anticoagulation or antiplatelet therapy, emboli were still detected in 17% of patients in this selected population. There was also a trend toward finding a history of previous TIA or stroke in prosthetic valve patients with microemboli, as well as a higher embolism rate more commonly in patients with a history of prior cerebrovascular symptoms.

The highest prevalence of microembolization was in patients with prosthetic cardiac valves (5 of 15 or 33%). Previous reports have documented microembolism prevalence rates of 0% to 50% in patients with bioprosthetic valves and of 54% to 89% in patients with mechanical valves. Our data are consistent with these reports (2 of 5 or 40% of mechanical valves with emboli, 3 of 10 or 30% of bioprosthetic valves). As noted above, our lower prevalence was probably influenced by the large number of aortic (13 of 15) and porcine (10 of 15) valves in our sample. Both these valve types are associated with a lower risk of cerebral embolization.

Patients with AF had fewer microemboli. Prior studies have reported prevalence rates ranging from 30% to 88% in AF patients with recent stroke. Tegeler et al found 11% (1 of 9) of patients with AF and no acute stroke had microemboli. Our AF subgroup had a similar prevalence of microembolism of 15% (2 of 13). The number of emboli seen during a monitoring session was low (1 embolus per 30 minutes). This is comparable to or perhaps somewhat lower than rates reported by others for patients with bioprosthetic valves (average, 2 emboli per hour; range, 0 to 7). There was no detectable relationship between the presence of microemboli and a history of prior stroke in this group, although the small sample size could have obscured such a finding.

One explanation of the lower rate of embolization in AF patients could be that virtually all the patients were receiving antithrombotic therapy (12 of 13). In treated patients the rate of symptomatic cerebral embolism may be 2% per year or less. In addition, 2 patients had a history of paroxysmal AF and were not in AF at the time of examination. The mechanism of embolism might also

<table>
<thead>
<tr>
<th>Patients</th>
<th>Mean Emboli per 30 Min (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke-positive, emboli-positive (n=3)</td>
<td>10 (6-17)</td>
</tr>
<tr>
<td>Stroke-negative, emboli-positive (n=4)</td>
<td>3 (1-8)</td>
</tr>
</tbody>
</table>
be different in AF patients compared with mechanical valve patients. In addition, the lower rate of TCD-detected microemboli in AF patients suggests that monitoring times may need to be increased in this group. Microemboli were not seen in patients in group C. This is consistent with the assumption that these patients are less likely to have cerebral embolization and that strokes in these patients are probably due to other mechanisms.

There is a possibility that some of the microemboli could have originated from carotid lesions, since only 3 of 7 emboli-positive patients had carotid ultrasound examinations. However, in 2 of the patients who did not have carotid ultrasound evaluations, microemboli were detected bilaterally. Of the 2 remaining patients, 1 was young and had a bioprosthetic aortic valve replacement. The other had AF and severe congestive heart failure. Therefore, we believe that carotid lesions are unlikely to account for the microemboli detected in this study.

The relationship between microemboli and stroke risk is uncertain. Several reports have associated microembolism with recent stroke, acute myocardial infarction (MI), and cardioembolic or carotid risk factors. In one study of acute MI patients, 16 of 76 (21%) had microemboli. However, the emboli were not predictive of future cerebrovascular events, possibly because all patients were placed on anticoagulation therapy. In another study, patients with microemboli associated with AF or other cardiac sources of emboli were found to have a higher incidence of recurrent neurological events. Unfortunately, only 42% of patients were available for follow-up. More recently, in a study of 179 prosthetic valve patients, no relationship between the presence of emboli and prior neurological events was found.

Our preliminary data suggest that microemboli can be found more frequently in prosthetic valve patients with a prior history of stroke. Of patients with microemboli, 60% had a history of prior stroke versus only 20% of patients without microemboli. The number of emboli seen per insonation period was also greater in valve patients with a history of prior stroke than in patients without a prior history of stroke. While not statistically significant, these trends suggest that microemboli may be predictive for a history of prior stroke. Whether these microemboli are an independent risk factor or a risk related to the presence of a prosthetic valve alone is unclear.

In addition, this study suggests that the yield from unselected TCD embolus-detection sessions will be low. Patients with known but low-risk cardiac lesions did not have microemboli. However, the effect of longer monitoring sessions needs to be investigated.

In conclusion, we believe that TCD is a promising modality for evaluating embolic stroke. We detected emboli in a substantial number of patients, even though the majority were receiving treatment and did not have the highest-risk cardiac lesions for microemboli. Our data suggest an association between the presence of microemboli and known cardioembolic risk factors. There may also be a relationship between microemboli and a history of prior stroke. The rate of embolization could also be an important determinant of stroke risk. Larger prospective studies will be needed to determine whether these microemboli are an independent risk factor for recurrent stroke. Additional investigations into the nature of microemboli and their response to treatment will also be needed. Such investigations will help to further delineate the role of TCD in stroke prevention and treatment.

Acknowledgments

We wish to thank Dr. Midori Yenari for her helpful editorial commentary regarding this study. We wish to thank Paige Bracci for her assistance with the statistical methods.

References


Incidence of transcranial Doppler-detected cerebral microemboli in patients referred for echocardiography.
D C Tong, A Bolger and G W Albers

Stroke. 1994;25:2138-2141
doi: 10.1161/01.STR.25.11.2138

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/25/11/2138